Results: Twenty-seven INAHTA agencies (69 percent response rate) from nineteen countries responded to the survey. Dedicated PET systems are the most universally installed systems to date. Mobile scanners and modified gamma cameras are used occasionally as lower cost alternatives, and interest in PET-computed tomography hybrid models is rising despite limited assessment of impact on service planning. PET was used and assessed most commonly for managing patients with cancer. All respondents reported having some form of public funding for clinical PET frequently linked to data collection for the purpose of gathering evidence to refine clinical use and guide resource allocation toward indications that maximize clinical and costeffectiveness. Conclusions: The use of HTA within a continuous quality improvement framework can help optimize scarce resources for evaluation and use of high cost diagnostic technologies such as PET, particularly where potential clinical or cost-effectiveness is considerable but conclusive evidence is lacking.
Positron emission tomography (PET) is an example of a costly, popular, and potentially beneficial diagnostic imaging test that has been introduced rapidly into health care often without definitive evidence of clinical or cost-effectiveness. As healthcare systems struggle to manage the introduction and use of diagnostic imaging modalities in clinical care, many use health technology assessment (HTA) to help define the clinical benefits of these technologies and direct policy for clinical use and research within the context of improved health outcomes, limited healthcare resources, and patient focus.
Several HTA agencies within the International Network of Agencies for Health Technology Assessment (INAHTA) have assessed the scientific evidence of PET's clinical utility for the purpose of informing purchasing and reimbursement decisions, research policy, and clinical utilization within an evidence-based framework. INAHTA established a Joint Project on PET scanning in 1997 to synthesize information on the diffusion, evaluation, and policy implementation of PET in healthcare systems represented by its members. INAHTA Joint Projects are collaborations among member agencies to evaluate medical technologies of mutual interest. The first Joint Project report on PET was produced in 1999 (1) .
Since then, both INAHTA's membership and interest in PET have continued to expand along with the need to carefully manage the technology's diffusion into clinical care with increasingly scarce healthcare resources. As a result, INAHTA sought to update its first Joint Project report by again surveying membership on diffusion, assessment, and policy for clinical use of PET. To supplement the survey results, INAHTA sponsored a pre-conference workshop at the first scientific meeting of Health Technology Assessment International in Krakow (2) . The objectives of the workshop were to expand discussion on the role of HTA in and present a range of policy implementation strategies for managing the diffusion of PET.
Part 1 of the INAHTA Joint Project on PET presents the survey results. Part 2 presents and summarizes the proceedings of the workshop, emphasizing the use of HTA to guide policy strategies for managing the diffusion of PET in clinical care within local contexts (unpublished data, 2005). 
METHODS

In
RESULTS
Twenty-seven INAHTA agencies in nineteen countries responded to the survey, representing a 69 percent response rate, including four agencies who replied with no involvement in PET scanning ("nil") ( Table 1 ). The National Association of Statutory Health Insurance Physicians Department of HTA (NASHIP) provided data for Germany on behalf of the German INAHTA agency DAHTA@DIMDI. Responses from the Swedish HTA agencies (SBU and CMT) were addressed by the PET Centre at Uppsala University Hospital, the Karolinska Hospital Departments of Radiology and Nuclear Medicine, and University Hospital Department of Oncology in Lund. Responses for Canada were provided by CCOHTA and AHFMR.
The wide timeframe over which responses were received, along with the lack of detail in some responses, made it difficult to construct a definitive "snapshot" of the situation at a single point in time. The survey information, therefore, provides a general overview of PET diffusion and evaluation of the period from early 2003 to early 2004 based on a range of anecdotal responses. Tables 2 through 4 summarize the key survey results.
Diffusion of PET
Members reported the number and type of PET scanners in clinical use in their country, region, or local health system; the survey considered dedicated PET scanners, PETcomputerized tomography (PET-CT) hybrid scanners, and gamma cameras modified for coincidence detection (Table 2). The majority of models in use were dedicated scanners, and most were situated in the public sector. Use of mobile scanners and modified gamma cameras as a lower cost alternative to traditional PET scanning was reported anecdotally.
INAHTA members reported an average of 16.4 dedicated PET scanners (range, 2-80 scanners; median, 9.5 scanners) per country, region, or health system and 0.65 scanners per increase from approximately fifty scanners to approximately sixty-five in the future. r Israel: Ten scanners are to be installed in the near future to meet their regulatory requirement of one scanner per 600,000 population. r The Netherlands: Eight scanners are to become operational in the near future (including at least one PET-CT hybrid scanner).
Responders provided data on clinical throughput; however, incomplete reporting and variability with respect to time period of data collection, definition of utilization, types of scanners represented, and the number of PET sites reported by each respective country or region hindered interpretation of the data. Countries with the highest annual throughputs Lung cancer, colorectal cancer, lymphoma, and melanoma were among the most common indications for which scan were performed, whereas some of the less common indications included myeloma, testicular cancer, chronic skeletal infection, and tumors of the liver, pancreas, and spleen.
Assessment of PET
The number of agencies involved in assessing PET and the list of indications assessed since the 1999 INAHTA survey are expanding, particularly in oncology (Table 3) . HTA approaches included new systematic reviews of primary studies, syntheses of existing systematic reviews, and primary data collection. Reasons for assessment centered on determining PET's clinical and cost-effectiveness for the purposes of improving quality of care and maximizing public resources with respect to the appropriate number of PET centers and their use within a local context. The clinical applications most often assessed by IN-AHTA agencies were the following cancer forms: head and neck, lung, colorectal, lymphoma, and melanoma. Assessments were restricted to studies using dedicated PET models, but some respondents expressed a need for evaluating the clinical utility of alternatives to dedicated PET systems and their impact on service provision.
Seven agencies reported planned assessments of PET typically as part of a research protocol (Table 4 ). All but one agency (Coordinación de la Unidad de Evaluación de Tecnologías Sanitarias, Madrid, UETS) are evaluating multiple indications for use. MSAC in Australia is assessing a range of indications as part of a multicenter single-arm study of PET's impact on patient management.
Policy Implementation of PET
All respondents commented on having some form of public funding for clinical PET scans, usually in the form of a prescribed list of indications, on a "case-by-case" basis, or within a research protocol. Clinical use and funding for PET were determined initially by external or in-house review of the clinical evidence, at times supplemented with expert input. Strategies for implementing clinical policy of PET usually included linking funding to continuous data gathering for the purposes of refining clinical use and optimizing resource allocation toward indications that maximize patient outcomes. Such strategies included monitoring utilization, monitoring published evidence to define PET's diagnostic 
